Patents by Inventor Paritosh Ghosh

Paritosh Ghosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240144662
    Abstract: Aspects of the present disclosure provide systems, methods, and computer-readable storage media that support adaptive machine learning (ML) classification that mitigates effects of catastrophic forgetting while reducing overall resource requirements. To illustrate, a computing device may train first and second ML classifiers based on historical streamed data. The second ML classifier is trained to use continuous learning, and the first ML classifier is not. If data drift of a data stream is below a lower threshold, the data stream is provided as input to the first ML classifier to generate classification output (e.g., predictions). If the data drift is above the lower threshold, dynamic switching occurs and the data stream is provided as input to the second ML classifier instead of the first ML classifier to generate the classifier output. If the data drift is above an upper threshold, operations are performed to train new ML classifiers.
    Type: Application
    Filed: October 31, 2022
    Publication date: May 2, 2024
    Inventors: Akshay Subhash Dhok, Paritosh Pramanik, Sourav Ghosh, Jyoti Singh
  • Patent number: 5965366
    Abstract: Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM).
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: October 12, 1999
    Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Biormia USA Inc.
    Inventors: Augusto C. Ochoa, Howard A. Young, Dan L. Longo, Paritosh Ghosh
  • Patent number: 5889143
    Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: March 30, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Augusto C. Ochoa, Dan L. Longo, Paritosh Ghosh, Howard A. Young
  • Patent number: 5658744
    Abstract: Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM).
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: August 19, 1997
    Assignees: The United States of America as represented by the Department of Health and Human Services, Biomira USA Inc.
    Inventors: Augusto C. Ochoa, Howard A. Young, Dan L. Longo, Paritosh Ghosh, Richard Robb, Mary Neville
  • Patent number: 5556763
    Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.
    Type: Grant
    Filed: March 17, 1993
    Date of Patent: September 17, 1996
    Assignee: United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Augusto C. Ochoa, Dan L. Longo, Paritosh Ghosh, Howard A. Young